￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
A new first-line treatment option for ALK-positive non-small cell lung cancer-crizotinib

2025-10-19 11:44:20

Check Details
The emergence of larotrectinib gives lung cancer patients an additional choice

2025-10-19 11:44:20

Check Details
Can larotrectinib treat small cell lung cancer?

2025-10-19 11:44:20

Check Details
The effect of crizotinib in the treatment of ALK-positive non-small cell lung cancer

2025-10-19 11:44:20

Check Details
How effective is the neoadjuvant drug nivolumab monotherapy in the treatment of lung cancer

2025-10-19 11:44:20

Check Details
Is the anti-cancer drug larotrectinib included in medical insurance? How much does a box cost?

2025-10-19 11:44:20

Check Details
Can lung squamous cell carcinoma without mutations be treated with afatinib?

2025-10-19 11:44:20

Check Details
Is afatinib a second-line treatment for lung squamous cell carcinoma?

2025-10-19 11:44:20

Check Details
The efficacy of nivolumab combined with ipilimumab in the treatment of non-small cell lung cancer

2025-10-19 11:44:20

Check Details
What patients with lung cancer need to know about using larotrectinib

2025-10-19 11:44:20

Check Details
Afatinib is the first oral targeted drug for lung squamous cell carcinoma approved by the FDA_ Kanghule

2025-10-19 11:44:20

Check Details
The broad-spectrum anti-tumor drug larotrectinib is applicable to the population, usage and dosage

2025-10-19 11:44:20

Check Details
Category
相关知识